Cancer is a most lethal disease in which some of the body's cells grow uncontrollably and spread to other parts of the body. Cancer drugs, such as chemotherapy, hormone therapies, targeted cancer drugs, immunotherapy drugs, and bisphosphonates, among others, are used to treat different types of cancer. Thus, with the rise in burden of cancer, the demand for safe and effective cancer drugs is also increasing with a rapid pace, worldwide.

Market Dynamics:

Increasing prevalence of cancer, growing geriatric population, high demand for safe and effective cancer drugs, increasing awareness among people about a cancer and cancer drugs, and increasing number of cancer treatment centres are factors expected to augment the growth of the global cancer drugs market during the forecast period.

For instance, according to the American Cancer Society (ACS), in 2023, more than 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. While, in 2022, around 1.9 Billion new cancer cases and 609,360 cancer deaths were projected to occur in the U.S. Moreover, according to the cancer report by Indian Council of Medical Research (ICMR), India’s cancer cases could increase by 12% in the next five years, with around 1.5 Billion people projected to suffer from the non-communicable disease by 2025, up from 1.39 Billion in 2020.

Key features of the study:

• This report provides in-depth analysis of the global cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Johnson & Johnson (Janssen Global Services, LLC), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer drugs market.

Detailed Segmentation:

• Global Cancer Drugs Market, By Drug Class Type:
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy)
• Global Cancer Drugs Market, By Indication:
  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancer
• Global Cancer Drugs Market, By Geography:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Celgene Corporation
  • AstraZeneca PLC
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson (Janssen Global Services, LLC)